Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-06-24
2010-06-29
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S070210, C435S335000, C530S387900
Reexamination Certificate
active
07744886
ABSTRACT:
Disclosed herein are methods for interfering with RANK signaling by administering blocking antibodies that bind a RANKL polypeptide and inhibit the binding of the RANKL polypeptide to a RANK polypeptide.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4710457 (1987-12-01), Dupont et al.
patent: 4710473 (1987-12-01), Morris
patent: 4959314 (1990-09-01), Mark et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5393739 (1995-02-01), Bentz et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5457035 (1995-10-01), Baum et al.
patent: 5578569 (1996-11-01), Tam
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5599708 (1997-02-01), Mundy et al.
patent: 5658756 (1997-08-01), Rodan et al.
patent: 5670319 (1997-09-01), Goeddel et al.
patent: 5710013 (1998-01-01), Goeddel et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5767244 (1998-06-01), Goeddel et al.
patent: 5789550 (1998-08-01), Goeddel et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5843901 (1998-12-01), Roeske
patent: 5961974 (1999-10-01), Armitage et al.
patent: 5985832 (1999-11-01), Roodman et al.
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6087555 (2000-07-01), Dunstan et al.
patent: 6150090 (2000-11-01), Baltimore et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6242586 (2001-06-01), Gorman et al.
patent: 6271349 (2001-08-01), Dougall et al.
patent: 6284485 (2001-09-01), Boyle et al.
patent: 6284728 (2001-09-01), Boyle et al.
patent: 6284740 (2001-09-01), Boyle et al.
patent: 6288032 (2001-09-01), Boyle et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6369027 (2002-04-01), Boyle et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6419929 (2002-07-01), Anderson
patent: 6525180 (2003-02-01), Gorman et al.
patent: 6528482 (2003-03-01), Anderson et al.
patent: 6537763 (2003-03-01), Dougall et al.
patent: 6562948 (2003-05-01), Anderson
patent: 6569430 (2003-05-01), Waldmann et al.
patent: 6649164 (2003-11-01), Maraskovsky
patent: 6740522 (2004-05-01), Anderson
patent: 6838262 (2005-01-01), Anderson
patent: 7019119 (2006-03-01), Choi et al.
patent: 7063841 (2006-06-01), Gorman et al.
patent: 7063960 (2006-06-01), Choi et al.
patent: 7097834 (2006-08-01), Boyle
patent: 7262274 (2007-08-01), Anderson et al.
patent: 7622442 (2009-11-01), Choi et al.
patent: 2002/0127637 (2002-09-01), Ni et al.
patent: 2002/0150989 (2002-10-01), Greene et al.
patent: 2003/0100069 (2003-05-01), Ni et al.
patent: 2003/0100488 (2003-05-01), Boyle
patent: 2003/0103978 (2003-06-01), Deshpande et al.
patent: 2003/0104485 (2003-06-01), Boyle
patent: 2003/0144480 (2003-07-01), Gorman et al.
patent: 2003/0166097 (2003-09-01), Greene et al.
patent: 2004/0023313 (2004-02-01), Boyle et al.
patent: 2004/0033535 (2004-02-01), Boyle et al.
patent: 2005/0089522 (2005-04-01), Anderson
patent: 2008/0015337 (2008-01-01), Choi et al.
patent: 56180/98 (1998-07-01), None
patent: 68518/98 (1998-11-01), None
patent: 71205/98 (1998-11-01), None
patent: 0514130 (1992-11-01), None
patent: 0526905 (1993-02-01), None
patent: 0727211 (1996-08-01), None
patent: 0816380 (1998-01-01), None
patent: 0873998 (1998-10-01), None
patent: 0874045 (1998-10-01), None
patent: 0911342 (1999-04-01), None
patent: 0955372 (1999-11-01), None
patent: 1997/097808 (1997-04-01), None
patent: 1997/151434 (1997-06-01), None
patent: 1997/217897 (1997-08-01), None
patent: 1997/224803 (1997-08-01), None
patent: 1997/332241 (2007-12-01), None
patent: 330400 (1999-05-01), None
patent: WO 86/00922 (1986-02-01), None
patent: WO 90/14363 (1990-11-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO 93/21946 (1993-11-01), None
patent: WO 95/11308 (1995-04-01), None
patent: WO 95/33051 (1995-12-01), None
patent: WO 96/28546 (1996-09-01), None
patent: WO 96/34095 (1996-10-01), None
patent: WO 97/00317 (1997-01-01), None
patent: WO 97/00318 (1997-01-01), None
patent: WO 97/23614 (1997-07-01), None
patent: WO 98/07840 (1998-02-01), None
patent: WO 98/25958 (1998-06-01), None
patent: WO 98/28423 (1998-07-01), None
patent: WO 98/28424 (1998-07-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/46644 (1998-10-01), None
patent: WO 98/46751 (1998-10-01), None
patent: WO 98/49305 (1998-11-01), None
patent: WO 98/54201 (1998-12-01), None
patent: WO 99/19468 (1999-04-01), None
patent: WO 99/29865 (1999-06-01), None
patent: WO 99/53942 (1999-10-01), None
patent: WO 99/58674 (1999-11-01), None
patent: WO 99/65449 (1999-12-01), None
patent: WO 99/65495 (1999-12-01), None
patent: WO 01/03719 (2001-01-01), None
patent: WO 01/17543 (2001-03-01), None
patent: WO 01/18203 (2001-03-01), None
patent: WO 01/23549 (2001-04-01), None
patent: WO 02/15846 (2002-02-01), None
patent: WO 03/002713 (2003-09-01), None
patent: WO 03/086289 (2003-10-01), None
Adams et al, “Complementary DNA sequencing: expreses sequence tags and human genome project,” Science, 252: 1651-1656 (1991).
Anderson et al, “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,”Nature390:175-179, 1997.
Baker, Stacey J. and Reddy, E. Premkumar, “Transducers of life and death: TNF receptor superfamily and associated proteins,”Oncogene, 12(1):1-9, 1996.
Benjamini et al, Immunology: A Short Course, 2nd edition, Wiley-Liss, New York, p. 40 (1988).
Boyle v.Gorman and Mattson, Board of Patent Appeals and Interferences, Interference No. 104,336, Paper No. 39.
Camerini et al, “The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family,”J. Immunol. 147:3165, 1991.
Chambers et al, “Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse,” Proc. Natl. Acad. Sci. USA, 90:5578-5582 (1993).
Chenu et al, “Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cultures,” Proc. Natl. Acad. Sci. USA, 85: 5683-5687 (1988).
Database GenBank, Accession No. AB008426., May 2, 1998.
Database GenBank, Accession No. AF013170, Nov. 5, 1998.
Database GenBank, Accession No. AF013171, Sep. 19, 1997.
Database GenBank, Accession No. AF019047, Nov. 22, 1997.
Database GenBank, Accession No. AF019048, Nov. 15, 1997.
Durkop et al, “Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's Disease,”Cell68:421, 1992.
EMBL database entry HS421358; accession No. W74421,Homo sapienscDNA clone 346544 containing alu repetitive element, Hillier et al, Jun. 1996.
EMBL-est database accession No. R93478, yql6f06.rlHomo sapiancDNA clone 197123 5′ sequence, Hillier et al, Aug. 1995.
Fawthrop et al “The effect of transforming growth factor β on the plasminogen activator activity of normal osteoblast-like cells and a human osteosarcoma Cell Line MG-63”, J. Bone Miner. Res., 7(12):1363-1371 (1992).
Fenton et al “Long-term culture of disaggregated rat osteclasts: inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP[107-139]”, J. Cell. Physiol., 155:1-7 (1993).
Fuller, K., et al, “TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorportion in osteoclasts.” J. Exp. Med., 188:997-1001 (1998).
Galibert et al, “The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-?B, a member of the TNFR superfamily,” J. Biol. Chem. 273(51):34120-34127, 1998.
Gao, Y. H., et al, “Potential role of cbfal, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis; regulation of mRNA espression of osteoclast differentiation factor (ODF).” Biochem. Biophys. Res. Commun. 252:697-702 (1998).
GenEmbl database accession No. X15271, locus.HSTRGV3F, human T-cell receptor gammaV3F, Lefranc, M. P., Mar. 1991.
George et al, Current methods in sequence compar
Ausenhus Scott L.
Immunex Corporation
Saoud Christine J
Stoica Elly-Gerald
LandOfFree
Methods for interfering with rank signaling does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for interfering with rank signaling, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for interfering with rank signaling will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4219828